Icon
+91 94997 68112
Login Register

Levaquin - (250,500,750 mg ;Tablet)

Levofloxacin Janssen Pharma
250,500,750 mg ;Tablet
More Than $1000 mn
Less Than 5
Less Than 5
Less Than 5
 None
More Than 5
More Than 5
Indications for LEVAQUIN: Susceptible bacterial infections including acute bacterial sinusitis (ABS), acute bacterial exacerbations of chronic bronchitis (ABECB), nosocomial or community-acquired pneumonia (CAP), UTIs, acute pyelonephritis, chronic bacterial prostatitis, skin and skin structure infections.
Yes
***** *** **** **** ***** ** **** * **** ** & **** **** ** *** *********, ***** **** ***** ***** * ****** *** *** **** ** *** ********* ******* *** ******** ***** **** * ****** ** ****** ** *** ********* ** *** **** ******* ***** & ******* ******* ******** *** *********. ** **** *** *** ************ ******* ******* ****, *****, **-**** *****************, *** ******** ************** ******** ********* *** ***** *** ******* ************ ************ ***** **** * ****** ** ****** ** *********, ** **** * * **** ****** **** ********* *** ******* ** ****** '*** & ***** ******* **** ********* & ******** ** ****** *** ***** ***** **** * ****** ** ****** ** ********* & ******* *** ****** **** ********* *** ******* ******* ******** *** ********* ***.**** **** ** *** ********* *** ****** *** ******* ** ******** ****** *** ****** ** ****** ** **** ****. ******* *********** ** **** ******* ********* **** *******.
  1. ***, **** : *********** ***** * **** ******* ***** ** ***** ***** * ****** **** ******** * ****** *****,*****,***** *** ****** ******* ** ******** ***** ** **** ********.
  2. ****, **** : *********** ***** * **** ******* **** ** **** ***** * ****** **** ******** * *****,*****,***** ****** *** ****** ******* ** ******** ***** ** **.
  3. ***, **** : *********** ***** * **** ******* ***** ** ***** ***** * ****** **** ******** * *****,*****,***** ****** *** ****** ******* ** ******** ***** ** **.
  4. *** **** : ***** *** **** **** *****(*)*** ****:*** ******** ***** ** **** ******** **** * ******** ******* *** ****** ** ***** ** *****, *********** *** ********* ** *****'* **** ******* *** ****** ** ********** ********** **** ** *** ******* ***** ****** **********,***** ******** *** ********* ** ******* *******.
  5. *** **** : ******** ******* ******** *** ********. ***** ***** * ****** *** *********.
  6. *****-*****, **** : ** *** ************ ******* ******* ****, *****, **-**** *********, *** ******** ************** ******** ********* *** ***** *** ******* ************ ************ ***** *** ********'* *********** ******* *** *********'* **** ** *********** ******* , ******* ***** ********* ** *** ******** ******* **** *** ***** *** ***** ** *** ***-********** ** ******* *********** ***** *** ***** & ******* ******* *** ******* ********* *** *** ** **** **********, *** ********* *** ****.
  7. **** : ****** ******* *** ******* * * **** ****** **** ********* ** ******** ** *** *********
  8. **** : ***** ********* **** *** ***** ********** ******* * ****** **** ********* ** *** ****** **** *****-****** ******** **** ******* ***** ******* **** *** ****** ********** ** ******** *** *** ******* ** ***** *********, *** ********* *** *** ******** *** *** ****** **** *********. ***** ****** *** ******** ** *********'* ******* *** ****** **** *** ******* ***** *** ******* *** ****** ** ******** ***** ** *** ********** ** *** ******** ****** ****.
  9. **** : *** ******** ***** ***** **** ***** ***** *** **** ***** *** ********** ******** ** ***** **** *** ******** ** ****** *** ****** ******** ******* *** ********* ****** **** ********* *** ******* *** **** *** ****** *** ********** ** ***** *** *********** ******* *****.
  10. *** **, **** : ***** ******** *** ** **** *** ********* *******: *** * ******** ***** *** *******, *** *********** ******* ****** *** ********* * *** ****

Levaquin - (EQ 25MG/ML; Injectable, Injection)

Levofloxacin Janssen Pharma
EQ 25MG/ML; Injectable, Injection
More Than $1000 mn
None
Less Than 5
None None
Less Than 5
Less Than 5
Indicated for the treatment of uncomplicated skin and skin structure infections (mild to moderate) including abscesses, cellulitis, furuncles, impetigo, pyoderma, wound infections, due to methicillin-susceptible Staphylococcus aureus, or Streptococcus pyogenes
Yes
******** ************** ******** ***** * ****** **** ******** * *********** & *** **** ** *********** ******* ** **** *** *** ************ ******* ******* ****, *****, **-**** *****************, *** ******** ************** ******** ********* *** ***** *** ******* ************ ************ ***** **** * ****** ** ****** ** *********, ** **** * * **** ****** **** ********* *** ******* ** ****** '*** & ***** ******* **** ********* & ******** ** ****** *** ***** ***** **** * ****** ** ****** ** ********* & ******* *** ****** **** ********* *** ******* ******* ******** *** ********* ***.**** **** ** *** ********* *** ****** *** ******* ** ******** ****** *** ****** ** ****** ** **** ****. ******* *********** ** **** ******* ********* **** *******.
  1. ***, **** : *********** ***** * **** ******* ******** *************** ******** ** ** ***** * ****** **** ******** * ********** ****** *** ***** *** ****** ******* ** ******** ***** ** **.
  2. *****-*****, **** : ** *** ************ ******* ******* ****, *****, **-**** *********, *** ******** ************** ******** ********* *** ***** *** ******* ************ ************ ***** *** ********'* *********** ******* *** *********'* **** ** *********** ******* , ******* ***** ********* ** *** ******** ******* **** *** ***** *** ***** ** *** ***-********** ** ******* *********** ***** *** ***** & ******* ******* *** ******* ********* *** *** ** **** **********, *** ********* *** ****.
  3. **** : ****** ******* *** ******* * * **** ****** **** ********* ** ******** ** *** *********.
  4. **** : ***** ********* **** *** ***** ********** ******* * ****** **** ********* ** *** ****** **** *****-****** ******** **** ******* ***** ******* **** *** ****** ********** ** ******** *** *** ******* ** ***** *********, *** ********* *** *** ******** *** *** ****** **** *********. ***** ****** *** ******** ** *********'* ******* *** ****** **** *** ******* ***** *** ******* *** ****** ** ******** ***** ** *** ********** ** *** ******** ****** ****.
  5. **** : *** ******** ***** ***** **** ***** ***** *** **** ***** *** ********** ******** ** ***** **** *** ******** ** ****** *** ****** ******** ******* *** ********* ****** **** ********* *** ******* *** **** *** ****** *** ********** ** ***** *** *********** ******* *****,***** ******** *** ********* ** ******* *******.
  6. ***, **** : ******* ******* **** * ********* ** ****** ** ********* *** ******** ******** *****'* *********,******* ******* **** ****** *****'* ****** *** *********.

Levaquin - (250MG/10ML; Solution, Oral)

Levofloxacin Janssen Pharma
250MG/10ML; Solution, Oral
More Than $1000 mn
None None
None None
Less Than 5
Less Than 5
Susceptible bacterial infections including acute bacterial sinusitis (ABS), acute bacterial exacerbations of chronic bronchitis (ABECB), nosocomial or community-acquired pneumonia (CAP), UTIs, acute pyelonephritis, chronic bacterial prostatitis, skin and skin structure infections.
Yes
*** *********
Levaquin Patent 1
** *******
  1. : ****** *** *********

Download ParaIV Report

Download ParaIV Detailed Report

To get detailed report Contact Us

ParaIV Advanced Search






Drug Name Generic Name Dosage Route of Administration Probable FTF Known Para IV Filers Other ANDA Developers

Please contact contact@researchdelta.com to get more details.

Headquarters

Research Delta Advisor, G4,Sani Apartment, Bank of india lane, Ellora park, Vadodara 390023

+91 94997 68112

nimish@researchdelta.com

Products & Services

Para IV GenUS Pharmalysis Consulting Valuation

Quick Links

Home About Career Media Coverage Contact
© Research Delta, All Right Reserved.   Privacy Policy.   Terms and Conditions.